Loading…
the sparker alert will let you know when a significant move starts with an audio alert, so You'll never miss an Opportunity.
Entera Bio Ltd Is A Clinical-Stage Biopharmaceutical Company Engaged In The Development Of Orally Delivered Macromolecule Therapeutics, Including Peptides And Therapeutic Proteins. The Company Focuses On Underserved, Chronic Medical Conditions Where Oral Administration Of A Mini Tablet Peptide Or Peptide Replacement Therapy Has The Potential To Perform. Its Product Candidates Are: Eb613, Which Is Being Developed As An Oral, Osteoanabolic (Bone-Building) Tablet Treatment For Osteoporosis; Eb612, Being Developed As An Oral Pth(1-34) Tablet Peptide Replacement Therapy For Patients With Hypoparathyroidism; Eb618, An Oral Glp-1 Being Developed To Tackle Obesity; And Oral Glp-2, A Peptide Tablet Alternative For Patients Suffering From Short Bowel Syndrome. The Company Operates In Israel.